Overview
I am an interventional cardiologist with a specific focus on the diagnosis and treatment of patients with cardiovascular disease. As a clinician, I see patients in the office and do coronary and peripheral vascular procedures (angiography and interventions) in the Duke Cardiac Catheterization Laboratory. I have served as the Medical Director of the cath lab at Duke since 2016. Alongside my partners in the cath lab, we collaborate with our cardiothoracic surgeons to hold Heart Team meetings each week, and we frequently are asked to address complex cardiovascular issues as a multidisciplinary team.
I also have a broad background in cardiovascular site-based research, multicenter clinical trials, clinical event classification, and observational analyses. I have helped to lead clinical trial efforts at the Duke Clinical Research Institute (DCRI) by designing and conducting studies evaluating new and existing treatments for patients with coronary artery disease and peripheral artery disease. My specific research interests include examining access to care and disparities in care for patients with peripheral artery disease and the design and conduct of pragmatic clinical trials in cardiovascular disease.
I also have a broad background in cardiovascular site-based research, multicenter clinical trials, clinical event classification, and observational analyses. I have helped to lead clinical trial efforts at the Duke Clinical Research Institute (DCRI) by designing and conducting studies evaluating new and existing treatments for patients with coronary artery disease and peripheral artery disease. My specific research interests include examining access to care and disparities in care for patients with peripheral artery disease and the design and conduct of pragmatic clinical trials in cardiovascular disease.
Current Appointments & Affiliations
Professor of Medicine
·
2024 - Present
Medicine, Cardiology,
Medicine
Professor in Population Health Sciences
·
2024 - Present
Population Health Sciences,
Basic Science Departments
Member in the Duke Clinical Research Institute
·
2013 - Present
Duke Clinical Research Institute,
Institutes and Centers
Recent Publications
Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Chronic Obstructive Pulmonary Disease and Asthma: Insights From ADAPTABLE.
Journal Article J Am Heart Assoc · December 2, 2025 BACKGROUND: Guidelines recommend aspirin (75-100 mg daily) for the secondary prevention of atherosclerotic cardiovascular disease (ASCVD). However, it is unknown if people with a history of ASCVD and chronic obstructive pulmonary disease (COPD) or asthma, ... Full text Link to item CiteLong-Term Medication-Induced Weight Change Across Common Antiseizure Medications: A Target Trial Emulation Study.
Journal Article Obesity (Silver Spring) · December 2025 OBJECTIVE: To estimate long-term weight change after initiation and adherence to commonly used antiseizure medications (ASMs) and examine differences in weight change across ASMs compared to topiramate. METHODS: We included 52,309 adult patients who initia ... Full text Link to item CiteUse of Cangrelor for Patients Undergoing Coronary Artery Bypass Grafting: Insights From the CAMEO Registry.
Journal Article JACC Adv · December 2025 BACKGROUND: Little is known about the use of cangrelor in patients with acute myocardial infarction (AMI) undergoing coronary artery bypass grafting (CABG). OBJECTIVES: The purpose of this study was to examine characteristics and patterns of cangrelor util ... Full text Link to item CiteRecent Grants
1/3 CTSA UM1 at Duke University
ResearchFaculty Member · Awarded by National Institutes of Health · 2025 - 20321/2 IMPRoving Outcomes in Vascular DisEase - Aortic Dissection (IMPROVE-AD)
ResearchCo Investigator · Awarded by National Institutes of Health · 2024 - 2030Evaluation of inclisiran versus placebo for the prevention of major adverse cardiovascular and limb events in patients undergoing percutaneous coronary intervention or peripheral endovascular intervention (VICTORIAN-INTERVENTION)
Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2025 - 2029View All Grants
Education, Training & Certifications
University of Arkansas, Little Rock ·
2001
M.D.